Ege University, School of Medicine, Department of Pediatrics, Division of Pediatric Genetics, Izmir, Turkey
Equal contributors
Turk J Haematol. 2020 Aug 28;37(3):145-153. doi: 10.4274/tjh.galenos.2020.2019.0262. Epub 2020 Feb 6.
Hemophilia A (HA) is the most severe X-linked inherited bleeding disorder caused by hemizygous mutations in the gene. The aim of this study is to determine the mutation spectrum of the gene in a large HA cohort from Turkey, and then to establish a phenotype-genotype correlation.
All HA cases (270 patients) analyzed molecularly in the Ege University Pediatric Genetics Molecular Laboratory between March 2017 and March 2018 were included in this study. To identify intron 22 inversion (Inv22), intron 1 inversion (Inv1), small deletion/insertions, and point mutations, molecular analyses of were performed using a sequential application of molecular techniques.
The mutation detection success rate was 95.2%. Positive Inv22 was found in 106 patients (39.3%), Inv1 was found in 4 patients (1.5%), and 106 different disease-causing sequence variants were identified in 137 patients (50.6%). In 10 patients (3.7%), amplification failures involving one or more exonic regions, considered to be large intragenic deletions, were identified. Of 106 different mutations, 36 were novel. The relationship between genotype and inhibitor development was considered significant.
A high mutation detection rate was achieved via the broad molecular techniques applied in this study, including 36 novel mutations. With regard to mutation types, mutation distribution and their impact on clinical severity and inhibitor development were found to be similar to those previously reported in other hemophilia population studies.
血友病 A (HA) 是一种最严重的 X 连锁遗传性出血性疾病,由 基因的半合突变引起。本研究旨在确定来自土耳其的大型 HA 队列中 基因的突变谱,并建立表型-基因型相关性。
本研究纳入了 2017 年 3 月至 2018 年 3 月在伊兹密尔大学儿科遗传学分子实验室进行分子分析的所有 HA 病例(270 例)。为了鉴定内含子 22 倒位(Inv22)、内含子 1 倒位(Inv1)、小缺失/插入和点突变,采用分子技术的顺序应用对 进行了分子分析。
突变检测成功率为 95.2%。在 106 例患者中发现了阳性 Inv22(39.3%),在 4 例患者中发现了 Inv1(1.5%),在 137 例患者中发现了 106 种不同的致病序列变异(50.6%)。在 10 例患者(3.7%)中,发现了涉及一个或多个外显子区域的扩增失败,被认为是大的基因内缺失。在 106 种不同的 突变中,有 36 种是新的。 基因型与抑制剂发展之间的关系被认为具有显著性。
通过广泛应用的分子技术,本研究实现了高的突变检测率,包括 36 种新突变。就突变类型、突变分布及其对临床严重程度和抑制剂发展的影响而言,与其他血友病人群研究中报道的相似。